nafcillin has been researched along with telavancin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hegde, SS; Judice, JK; Kaniga, K; McCullough, J; Obedencio, G; Pace, J; Reyes, N; Shaw, JP; Skinner, R; Thomas, R; Vanasse, N; Wiens, T | 1 |
| Gandhi, RG; Leonard, SN; Patel, MD; Supple, ME | 1 |
3 other study(ies) available for nafcillin and telavancin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Topics: Acetamides; Aminoglycosides; Animals; Anti-Bacterial Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Endpoint Determination; Female; Gram-Positive Bacterial Infections; Linezolid; Lipoglycopeptides; Methicillin Resistance; Mice; Muscle, Skeletal; Nafcillin; Neutropenia; Oxazolidinones; Protein Binding; Staphylococcal Infections; Subcutaneous Tissue; Vancomycin | 2004 |
Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Gentamicins; Humans; Imipenem; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Nafcillin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin Resistance | 2013 |